Willow Biosciences Inc - Asset Resilience Ratio

Latest as of March 2025: 0.86%

Willow Biosciences Inc (WLLW) has an Asset Resilience Ratio of 0.86% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read WLLW current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CA$20.00K

≈ $14.47K USD Cash + Short-term Investments

Total Assets

CA$2.31 Million

≈ $1.67 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Willow Biosciences Inc's Asset Resilience Ratio has changed over time. See WLLW net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Willow Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Willow Biosciences Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$0.00	0%
Short-term Investments	CA$20.00K	0.86%
Total Liquid Assets	CA$20.00K	0.86%

Asset Resilience Insights

Limited Liquidity: Willow Biosciences Inc maintains only 0.86% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Willow Biosciences Inc Industry Peers by Asset Resilience Ratio

Compare Willow Biosciences Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Daihan Pharmaceutical Co.Ltd KQ:023910	Drug Manufacturers - Specialty & Generic	11.95%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	16.92%
China Resources Sanjiu Medical & Pharmaceutical Co Ltd SHE:000999	Drug Manufacturers - Specialty & Generic	5.22%
Ningbo Menovo Pharm Co Ltd SHG:603538	Drug Manufacturers - Specialty & Generic	2.69%
Zhejiang Xianju Pharmaceutical Co Ltd SHE:002332	Drug Manufacturers - Specialty & Generic	6.02%
Qianjiang Yongan Pharmaceutical Co Ltd SHE:002365	Drug Manufacturers - Specialty & Generic	30.38%
Hainan Honz Pharmaceutical Co SHE:300086	Drug Manufacturers - Specialty & Generic	0.27%
Guangdong Lifestrong Pharmacy Co. Ltd. SHE:301111	Drug Manufacturers - Specialty & Generic	7.85%

Annual Asset Resilience Ratio for Willow Biosciences Inc (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Willow Biosciences Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.80%	CA$20.00K ≈ $14.47K	CA$2.49 Million ≈ $1.80 Million	+0.50pp
2023-12-31	0.30%	CA$20.00K ≈ $14.47K	CA$6.67 Million ≈ $4.83 Million	-82.50pp
2022-12-31	82.80%	CA$15.03 Million ≈ $10.87 Million	CA$18.15 Million ≈ $13.13 Million	-5.15pp
2021-12-31	87.95%	CA$30.80 Million ≈ $22.28 Million	CA$35.02 Million ≈ $25.33 Million	+12.69pp
2020-12-31	75.27%	CA$16.46 Million ≈ $11.90 Million	CA$21.86 Million ≈ $15.82 Million	+16.75pp
2019-12-31	58.51%	CA$19.83 Million ≈ $14.34 Million	CA$33.88 Million ≈ $24.51 Million	+50.41pp
2016-12-31	8.10%	CA$137.61K ≈ $99.54K	CA$1.70 Million ≈ $1.23 Million	-7.42pp
2015-12-31	15.52%	CA$374.75K ≈ $271.09K	CA$2.42 Million ≈ $1.75 Million	--

pp = percentage points

About Willow Biosciences Inc

TO:WLLW Canada Drug Manufacturers - Specialty & Generic

Market Cap

$18.10 Million

CA$25.02 Million CAD

Market Cap Rank

#28310 Global

#1281 in Canada

Share Price

CA$0.17

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.32

All Time High

CA$2.08